1. Scrip

Shanghai Reopens, Beijing Offers Policy Relief As Pharma Embraces Uncertain Future

COVID Situation Still Fluid

 
• By Brian Yang

China’s largest commercial center and pharma industry hub reopens after over two months of strict lockdown.

Shanghai reopened in April 2020
SHANGHAI REOPENS AFTER MONTHS OF STRICT LOCKDOWN • Source: Shutterstock

1 June marked the day when most COVID-19-related restrictions in Shanghai were finally lifted and people allowed to go out freely after months of strict lockdown, leading to champagne celebrations on the streets and traffic jams even at midnight.

One pharma executive told Scrip that the feeling was bittersweet, with the crowds and traffic returning just like pre-lockdown in early

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.